medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2018, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2018; 16 (1)

Non Invasive Preventive and Therapeutic Options to Treat Non Melanoma Cancer in Pediatric Cases with Xeroderma Pigmentosum

Cheirif-Wolosky O, Palacios-López C

Language: Spanish
References: 47
Page: 83-91
PDF size: 163.32 Kb.


ABSTRACT

Xeroderma pigmentosum is an autosomal recessive disease characterized by skin hypersensitivity to ultraviolet (uv) light with an elevated risk of basal cell carcinoma, squamous cell carcinoma and melanoma since infancy. There are multiple noninvasive therapeutic options to treat these patients. Among the options there are topical treatments, some of them have been tested in patients with xeroderma pigmentosum, but others have not yet been evaluated. Among the options we have imiquimod, 5-fluorouracil and igenol mebutate. Systemic retinoids are used for chemoprevention and topical and systemic sunblocks are also part of the preventive treatment. There are other innovative treatments such as photolyase and endonuclease t4n5. We will revew each one of them in detail.


REFERENCES

  1. DiGiovanna JJ y Kraemer KH, Shining a light on xeroderma pigmentosum, J Invest Dermatol 2012; 132:785-96.

  2. Black JO, Xeroderma pigmentosum, Head and Neck Pathol 2016; 10:139-44.

  3. Paller AS y Mancini AJ, Xeroderma pigmentoso. En Hurwitz clinical pediatric dermatology, Cambridge, Elsevier 2011, pp. 455-7.

  4. Kraemer KH, Lee MM y Scotto J, Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases, Arch Dermatol 1987; 123:241-50.

  5. Anttinen A, Koulu L, Nikoskelainen E et al., Neurological symptoms and natural course of xeroderma pigmentosum, Brain 2008, 131:1979-89.

  6. Broughton BC, Cordonnier A, Kleijer WJ et al., Molecular analysis of mutations in dna polymerase eta in xeroderma pigmentosum-variant patients, Proc Natl Acad Sci 2002; 99:815-20.

  7. Bradford PT, Goldstein AM, Tamura D et al., Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of adn repair, J Med Genet 2011 48:168-76.

  8. Bunick CG, Miller MR, Fuller BE, Fanning E y Chazin WJ, Biochemical and structural domain analysis of xeroderma pigmentosum complementation group c protein, Biochemistry 2006; 45:14965-79.

  9. Marini F, Nardo T, Giannattasio M et al., dna nucleotide excision repair- dependent signaling to checkpoint activation, Proc Natl Acad Sci 2006; 103:17325-30.

  10. Karass M, Naguib MN, Elawabdeh N et al., Xeroderma pigmentosa: three new cases with an in depth review of the genetic and clinical characteristics of the disease, Fetal and Pediatr Pathol 2015; 34:120-7.

  11. Berneburg M y Lehmann AR, Xeroderma pigmentosum and related disorders: defects in dna repair and transcription, Adv Genet 2001; 43:71-102.

  12. Almutawa F, Vandal R, Wang SQ y Lim HW, Current status of photoprotection by glass by window glass, automobile glass, window films, and sunglasses, Photodermatol Photoimmunol Photomed 2013; 29:65-72.

  13. Jansen R, Wang SQ, Burnett M, Osterwalder U y Lim HW, Photoprotection: part i. Photoprotection by naturally occurring, physical, and systemic agents, J Am Acad Dermatol 2013; 69: 853.

  14. Nakagawara VB, Montgomery RW y Marshall WJ, Optical radiation transmittance of aircraft windscreens and pilot vision, Washington, Federal Aviation Administration, Office of Aerospace Medicine 2007.

  15. Gambichler T, Altmeyer P y Hoffmann K, Role of clothes in sun protection, Recent Results Cancer Res 2002; 160:15-25.

  16. Masaki T, Wang Y, DiGiovanna JJ et al., High frequency of pten mutations in nevi and melanomas from xeroderma pigmentosum patients, Pigment Cell Melanoma Res 2014; 7:454-64.

  17. Nagore E, Sevila A, Sanmartín O et al., Excellent response of basal cell carcicomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream, Br J Dermatol 2003; 149:858-61.

  18. Ocampo-Candiani J, Silva-Siwady G, Fernández-Gutiérrez L y Field L, Dermabrasion in xeroderma pigmentosum, Dermatol Surg 1996; 22(6):575-7.

  19. Yang J, Chen X, Engle M y Wang J, Multiple facial basal cell carcinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream, Dermatol Ther 2015; 28:243-7.

  20. Lear J, Evidence-based treatment for low-risk basal cell carcinoma, Lancet Oncol 2014; 15:12-3.

  21. Arits A, Mosterd K, Essers B et al., Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal- cell carcinoma: a single blind, non-inferiority, randomised controlled trial, Lancet Oncol 2013; 14:647-54.

  22. Tandon Y y Brodell R, Local reactions to imiquimod in the treatment of basal cell carcinoma, Dermatol Online J 2012; 18(9):1.

  23. Weisberg N y Varghese M, Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream, Dermatol Surg 2002; 28:518-23.

  24. Nijsten T, Lapière K y Lambert J, A patient with xeroderma pigmentosum treated with imiquimod 5% cream, J Am Acad Dermatol 2005; 52(1):170-1.

  25. Alessi S, Sanches J, Oliveira W et al., Treatment of cutaneous tumors with topical 5% imiquimod cream, Clinics 2009; 64:961-6.

  26. Hamouda B, Jamila Z, Najet R et al., Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum, J Am Acad Dermatol 2001; 44(6):1054.

  27. Challacombe J, Suhrbier A, Parsons P et al., Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol- 3-angelate, J Immunol 2006; 177:8123-32.

  28. Anderson L, Schmieder G, Werschler W et al., Randomized, double- blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis, J Am Acad Dermatol 2009; 60:934-43.

  29. Slaughter DP, Southwick HW y Smejkal W, Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin, Cancer 1953; 6:963-8.

  30. Peck GL, Digiovanna JJ, Sarnoff DS et al., Treatment and prevention of basal cell carcinoma with oral isotretinoin, J Am Acad Dermatol 1988; 19:176-85.

  31. Giannotti B, Vanzi L, Difonzo EM y Pimpinelli N, The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of 5% imiquimod cream and oral acitretin, Clin Exp Dermatol 2003; 1:33-5.

  32. Kraemer KH, Digiovanna JJ, Moshell AN, Tarone RE y Peck GL, Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin, N Engl J Med 1988; 318:1633-7.

  33. Sun SY y Lotan R, Retinoids and their receptors in cancer development and chemoprevention, Crit Rev Oncol Hematol 2002; 41(1):41-55.

  34. Lambert WC y Lambert MW, Development of effective skin cancer treatment and prevention in xeroderma pigmentosum, Photochemistry and Photobiology 2015; 91:475-83.

  35. Tamura D, Digiovanna JJ, Khan SG y Kraemer KH, Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients, Photodermatol Photoimmunol Photomed 2014; 30:146-52.

  36. Aguilera P, Carrera C, Puig-Butille JA et al., Benefits of oral polypodium leucotomos extract in mm high-risk patients, J Eur Acad Dermatol Venereol 2013; 27:1095-100.

  37. González S, Gilaberte Y y Philips N, Mechanistic insights in the use of a polypodium leucotomos extract as an oral and topical photoprotective agent, Photochem Photobiol Sci 2010; 9:559-63.

  38. Haylett AK, Nie Z, Brownrigg M, Taylor R y Rhodes LE, Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D- Phe7]-Alpha-Msh, Br J Dermatol 2011; 164:407-14.

  39. Harms J, Lautenschlager S, Minder CE y Minder EI, An alpha-melanocyte- stimulating hormone analogue in erythropoietic protoporphyria, N Engl J Med 2009; 360:306-7.

  40. Elmets CA, Viner JL, Pentland AP et al., Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo- controlled trial, J Natl Cancer Inst 2010; 102:1835-44.

  41. Yarosh D, Klein J, O’Connor A et al., Effect of topically applied t4 endonuclease v in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group, Lancet 2001; 357:926-9.

  42. Stege H, Roza L, Vink AA et al., Enzyme plus light therapy to repair dna damage in ultraviolet-b-irradiated human skin, Proc Natl Acad Sci USA 2000; 97:1790-5.

  43. Giustini S, Miraglia E, Berardesca E, Milani M y Calvieri S, Preventive long-term effects of a topical film-forming medical device with ultra- high uv protection filters and dna repair enzyme in xeroderma pigmentosum: a retrospective study of eight cases, Case Rep Dermatol 2014; 6:222-6.

  44. Lim HW, Arellano-Mendoza M y Stengel F, Current challenges in photoprotection, J Am Acad Dermatol 2017; 76:S91-9.

  45. Miyata R, Tanuma N, Sakuma H y Hayashi M, Circadian rhythms of oxidative stress markers and melatonin metabolite in patients with xeroderma pigmentosum group a, Oxidative medicine and cellular longevity 2016; 2016:1-5.

  46. Tang JY, Fu T, Lau C et al., Vitamin d in cutaneous carcinogenesis: part ii, J Am Acad Dermatol 2012; 67:E1-11.

  47. Kuwabara A, Tsugawa N, Tanaka K. et al., High prevalence of vitamin d deficiency in patients with xeroderma pigmentosum: a under strict sun protection, European Journal of Clinical Nutrition 2015; 69(6):693-6.




2020     |     www.medigraphic.com